{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T00:31:02Z","timestamp":1788827462952,"version":"build-2803163510"},"reference-count":99,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaci-inpractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1016\/j.jaip.2022.06.016","type":"journal-article","created":{"date-parts":[[2022,6,25]],"date-time":"2022-06-25T11:40:46Z","timestamp":1656157246000},"page":"2570-2578","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["The Role of Omalizumab in NSAID-Exacerbated Respiratory Disease: A Narrative Review"],"prefix":"10.1016","volume":"10","author":[{"given":"Masami","family":"Taniguchi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrico","family":"Heffler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heidi","family":"Olze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"White","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joana","family":"C\u00f4rte-Real","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petter","family":"Olsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Slawomir","family":"Lazarewicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaip.2022.06.016_bib1","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.rmed.2018.01.002","article-title":"Aspirin exacerbated respiratory disease: current topics and trends","volume":"135","author":"Rodriguez-Jimenez","year":"2018","journal-title":"Respir Med"},{"key":"10.1016\/j.jaip.2022.06.016_bib2","doi-asserted-by":"crossref","first-page":"7","DOI":"10.2500\/ajra.2018.32.4498","article-title":"Role of group 2 innate lymphocytes in aspirin-exacerbated respiratory disease pathogenesis","volume":"32","author":"White","year":"2018","journal-title":"Am J Rhinol Allergy"},{"key":"10.1016\/j.jaip.2022.06.016_bib3","first-page":"189","article-title":"Idiosyncratic anaphylaxis","volume":"30","author":"Widal","year":"1922","journal-title":"Presse Med"},{"key":"10.1016\/j.jaip.2022.06.016_bib4","doi-asserted-by":"crossref","first-page":"975","DOI":"10.7326\/0003-4819-68-5-975","article-title":"Intolerance to aspirin. Clinical studies and consideration of its pathogenesis","volume":"68","author":"Samter","year":"1968","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jaip.2022.06.016_bib5","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1097\/ACI.0000000000000498","article-title":"Prostaglandin E2 in NSAID-exacerbated respiratory disease: protection against cysteinyl leukotrienes and group 2 innate lymphoid cells","volume":"19","author":"Rusznak","year":"2019","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2022.06.016_bib6","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1007\/s12016-021-08901-1","article-title":"The role of IgE in upper and lower airway disease: more than just allergy!","volume":"62","author":"Gevaert","year":"2022","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.jaip.2022.06.016_bib7","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.jaci.2020.04.031","article-title":"Activation of the 15-lipoxygenase pathway in aspirin-exacerbated respiratory disease","volume":"147","author":"Stevens","year":"2021","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2022.06.016_bib8","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1111\/all.14318","article-title":"Type 2 immunity in the skin and lungs","volume":"75","author":"Akdis","year":"2020","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2022.06.016_bib9","doi-asserted-by":"crossref","first-page":"19","DOI":"10.3390\/antib8010019","article-title":"IgE antibodies: from structure to function and clinical translation","volume":"8","author":"Sutton","year":"2019","journal-title":"Antibodies (Basel)"},{"key":"10.1016\/j.jaip.2022.06.016_bib10","doi-asserted-by":"crossref","first-page":"S73","DOI":"10.1016\/j.jaci.2009.11.017","article-title":"IgE, mast cells, basophils, and eosinophils","volume":"125","author":"Stone","year":"2011","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2022.06.016_bib11","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1164\/rccm.202003-0783ED","article-title":"Does IgE have a role in aspirin-exacerbated respiratory disease?","volume":"201","author":"Busse","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaip.2022.06.016_bib12","doi-asserted-by":"crossref","first-page":"287","DOI":"10.2500\/ajra.2014.28.4054","article-title":"Elevated total serum IgE in nonatopic patients with aspirin-exacerbated respiratory disease","volume":"28","author":"Johns","year":"2014","journal-title":"Am J Rhinol Allergy"},{"key":"10.1016\/j.jaip.2022.06.016_bib13","series-title":"Omalizumab\u2014Summary of Product Characteristics","author":"Novartis","year":"2020"},{"key":"10.1016\/j.jaip.2022.06.016_bib14","series-title":"Genentech USA Inc. and Novartis Pharmaceuticals Corporation","year":"2020"},{"key":"10.1016\/j.jaip.2022.06.016_bib15","unstructured":"D.K. Jain, P. Garg. Xolair Periodic Safety Update Report. Period covered: 01 Jan 2021 - 31 Dec 2021. 2022. Issued: 24 Feb 2022."},{"key":"10.1016\/j.jaip.2022.06.016_bib16","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.jaci.2020.05.032","article-title":"Efficacy and safety of omalizumab in nasal polyposis: 2 randomized phase 3 trials","volume":"146","author":"Gevaert","year":"2020","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2022.06.016_bib17","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1038\/nri3859","article-title":"Eicosanoid storm in infection and inflammation","volume":"15","author":"Dennis","year":"2015","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.jaip.2022.06.016_bib18","first-page":"45","article-title":"Aspirin exacerbated respiratory disease: epidemiology, pathophysiology, and management","volume":"7","author":"Li","year":"2019","journal-title":"Med Sci (Basel)"},{"key":"10.1016\/j.jaip.2022.06.016_bib19","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1111\/j.1365-2222.2011.03839.x","article-title":"Urinary concentrations of 15-epimer of lipoxin A(4) are lower in patients with aspirin-intolerant compared with aspirin-tolerant asthma","volume":"41","author":"Yamaguchi","year":"2011","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.jaip.2022.06.016_bib20","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1016\/j.jaci.2005.02.029","article-title":"Prostaglandin, leukotriene, and lipoxin balance in chronic rhinosinusitis with and without nasal polyposis","volume":"115","author":"Perez-Novo","year":"2005","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2022.06.016_bib21","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.alit.2019.05.001","article-title":"Aspirin-exacerbated respiratory disease (AERD): current understanding of AERD","volume":"68","author":"Taniguchi","year":"2019","journal-title":"Allergol Int"},{"key":"10.1016\/j.jaip.2022.06.016_bib22","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1007\/s11882-017-0673-6","article-title":"Update on aspirin-exacerbated respiratory disease","volume":"17","author":"Woessner","year":"2017","journal-title":"Curr Allergy Asthma Rep"},{"key":"10.1016\/j.jaip.2022.06.016_bib23","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1111\/j.1365-2222.2006.02498.x","article-title":"Cysteinyl leukotrienes: multi-functional mediators in allergic rhinitis","volume":"36","author":"Peters-Golden","year":"2006","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.jaip.2022.06.016_bib24","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.3389\/fphar.2020.01147","article-title":"NSAID-exacerbated respiratory disease (NERD): from pathogenesis to improved care","volume":"11","author":"Woo","year":"2020","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.jaip.2022.06.016_bib25","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.jaci.2004.10.051","article-title":"Expression of the cysteinyl leukotriene receptors cysLT(1) and cysLT(2) in aspirin-sensitive and aspirin-tolerant chronic rhinosinusitis","volume":"115","author":"Corrigan","year":"2005","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2022.06.016_bib26","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.jaci.2009.05.046","article-title":"The leukotriene E4 puzzle: finding the missing pieces and revealing the pathobiologic implications","volume":"124","author":"Austen","year":"2009","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2022.06.016_bib27","doi-asserted-by":"crossref","first-page":"10967","DOI":"10.1074\/jbc.C113.453704","article-title":"Identification of GPR99 protein as a potential third cysteinyl leukotriene receptor with a preference for leukotriene E4 ligand","volume":"288","author":"Kanaoka","year":"2013","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.jaip.2022.06.016_bib28","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.jaci.2014.07.031","article-title":"Prostaglandin D(2): a dominant mediator of aspirin-exacerbated respiratory disease","volume":"135","author":"Cahill","year":"2015","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2022.06.016_bib29","series-title":"Aspirin or Nonsteroidal Drug-Exacerbated Respiratory Disease (AERD or NERD)","year":"2019"},{"key":"10.1016\/j.jaip.2022.06.016_bib30","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.iac.2012.11.006","article-title":"Pathogenesis of aspirin-exacerbated respiratory disease and reactions","volume":"33","author":"Laidlaw","year":"2013","journal-title":"Immunol Allergy Clin North Am"},{"key":"10.1016\/j.jaip.2022.06.016_bib31","first-page":"1","article-title":"On the role of PGD2 metabolites as markers of mast cell activation in asthma","volume":"644","author":"O\u2019Sullivan","year":"1999","journal-title":"Acta Physiol Scand Suppl"},{"key":"10.1016\/j.jaip.2022.06.016_bib32","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1111\/j.1365-2222.2008.03104.x","article-title":"Increased production of cysteinyl leukotrienes and prostaglandin D2 during human anaphylaxis","volume":"39","author":"Ono","year":"2009","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.jaip.2022.06.016_bib33","doi-asserted-by":"crossref","first-page":"393","DOI":"10.2332\/allergolint.11-RA-0403","article-title":"Aspirin-intolerant asthma (AIA) assessment using the urinary biomarkers, leukotriene E4 (LTE4) and prostaglandin D2 (PGD2) metabolites","volume":"61","author":"Higashi","year":"2012","journal-title":"Allergol Int"},{"key":"10.1016\/j.jaip.2022.06.016_bib34","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1016\/j.jaci.2016.04.042","article-title":"Eosinophil production of prostaglandin D2 in patients with aspirin-exacerbated respiratory disease","volume":"138","author":"Feng","year":"2016","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2022.06.016_bib35","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.jaci.2015.05.041","article-title":"Platelet activation markers overexpressed specifically in patients with aspirin-exacerbated respiratory disease","volume":"137","author":"Mitsui","year":"2016","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2022.06.016_bib36","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/S0091-6749(97)70230-6","article-title":"Endocytosis, storage, and release of IgE by human platelets: differences in patients with type I allergy and nonatopic subjects","volume":"100","author":"Klouche","year":"1997","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2022.06.016_bib37","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.jaci.2018.06.001","article-title":"A\u00a0trial of type 12 purinergic (P2Y12) receptor inhibition with prasugrel identifies a potentially distinct endotype of patients with aspirin-exacerbated respiratory disease","volume":"143","author":"Laidlaw","year":"2019","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2022.06.016_bib38","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/j.jaci.2019.08.022","article-title":"Aspirin sensitivity: lessons in the regulation (and dysregulation) of mast cell function","volume":"144","author":"Boyce","year":"2019","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2022.06.016_bib39","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1016\/j.jaci.2010.12.1108","article-title":"Targeted eicosanoid lipidomics of exhaled breath condensate provide a distinct pattern in the aspirin-intolerant asthma phenotype","volume":"127","author":"Sanak","year":"2011","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2022.06.016_bib40","doi-asserted-by":"crossref","first-page":"37","DOI":"10.2332\/allergolint.09-OA-0166","article-title":"Increase in salivary cysteinyl-leukotriene concentration in patients with aspirin-intolerant asthma","volume":"60","author":"Ono","year":"2011","journal-title":"Allergol Int"},{"key":"10.1016\/j.jaip.2022.06.016_bib41","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.alit.2016.10.001","article-title":"Increased airway hyperresponsiveness to adenosine in patients with aspirin intolerant asthma","volume":"66","author":"Isogai","year":"2017","journal-title":"Allergol Int"},{"key":"10.1016\/j.jaip.2022.06.016_bib42","doi-asserted-by":"crossref","first-page":"463","DOI":"10.2147\/JAA.S237463","article-title":"The role of mast cells in aspirin-exacerbated respiratory disease (AERD) pathogenesis: implications for future therapeutics","volume":"13","author":"Kuruvilla","year":"2020","journal-title":"J\u00a0Asthma Allergy"},{"key":"10.1016\/j.jaip.2022.06.016_bib43","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1067\/mai.2003.60","article-title":"Mast cells: beyond IgE","volume":"111","author":"Lanny","year":"2003","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2022.06.016_bib44","doi-asserted-by":"crossref","first-page":"3537","DOI":"10.4049\/jimmunol.1500905","article-title":"Aspirin-exacerbated respiratory disease involves a cysteinyl leukotriene-driven IL-33-mediated mast cell activation pathway","volume":"195","author":"Liu","year":"2015","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.jaip.2022.06.016_bib45","first-page":"620","article-title":"Mast cell: a multi-functional master cell","volume":"6","author":"Krystel-Whittemore","year":"2015","journal-title":"Front Immunol"},{"key":"10.1016\/j.jaip.2022.06.016_bib46","doi-asserted-by":"crossref","first-page":"37","DOI":"10.2147\/JAA.S88739","article-title":"Aspirin-exacerbated respiratory disease: pathophysiological insights and clinical advances","volume":"9","author":"Steinke","year":"2016","journal-title":"J\u00a0Asthma Allergy"},{"key":"10.1016\/j.jaip.2022.06.016_bib47","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1186\/s12931-018-0909-6","article-title":"The utility of biomarkers in diagnosis of aspirin exacerbated respiratory disease","volume":"19","author":"Comhair","year":"2018","journal-title":"Respir Res"},{"key":"10.1016\/j.jaip.2022.06.016_bib48","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1111\/j.1365-2222.2004.01968.x","article-title":"Urinary 3-bromotyrosine and 3-chlorotyrosine concentrations in asthmatic patients: lack of increase in 3-bromotyrosine concentration in urine and plasma proteins in aspirin-induced asthma after intravenous aspirin challenge","volume":"34","author":"Mita","year":"2004","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.jaip.2022.06.016_bib49","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1016\/j.jaip.2020.09.007","article-title":"Mepolizumab does not prevent all aspirin-induced reactions in patients with aspirin-exacerbated respiratory disease: a case series","volume":"9","author":"Martin","year":"2021","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2022.06.016_bib50","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/j.jaip.2021.09.030","article-title":"Appraisal of the real-world effectiveness of biologic therapies in aspirin-exacerbated respiratory disease","volume":"10","author":"Wangberg","year":"2022","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2022.06.016_bib51","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1016\/j.jaci.2017.03.036","article-title":"Analysis of basophil activation in patients with aspirin-exacerbated respiratory disease","volume":"140","author":"Mitsui","year":"2017","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2022.06.016_bib52","doi-asserted-by":"crossref","first-page":"AB91","DOI":"10.1016\/j.jaci.2016.12.248","article-title":"Basophil activation in aspirin exacerbated respiratory disease","volume":"139","author":"Stevens","year":"2017","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2022.06.016_bib53","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.jaci.2021.02.045","article-title":"Studies of the role of basophils in aspirin-exacerbated respiratory disease pathogenesis","volume":"148","author":"Stevens","year":"2021","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2022.06.016_bib54","first-page":"116","article-title":"Cytokine and lipid mediator regulation of group 2 innate lymphoid cells (ILC2s) in human allergic airway disease","volume":"2","author":"Cavagnero","year":"2017","journal-title":"J\u00a0Cytokine Biol"},{"key":"10.1016\/j.jaip.2022.06.016_bib55","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1189\/jlb.5BT0814-374R","article-title":"At the bench: understanding group 2 innate lymphoid cells in disease","volume":"97","author":"Doherty","year":"2015","journal-title":"J\u00a0Leukoc Biol"},{"key":"10.1016\/j.jaip.2022.06.016_bib56","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.anai.2020.09.011","article-title":"Lipid-mediated innate lymphoid cell recruitment and activation in aspirin-exacerbated respiratory disease","volume":"126","author":"Cavagnero","year":"2021","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaip.2022.06.016_bib57","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.jaci.2016.11.023","article-title":"Group 2 innate lymphoid cells are recruited to the nasal mucosa in patients with aspirin-exacerbated respiratory disease","volume":"140","author":"Eastman","year":"2017","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2022.06.016_bib58","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.anai.2020.08.001","article-title":"Group 2 innate lymphoid cells in nasal polyposis","volume":"126","author":"Stevens","year":"2021","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaip.2022.06.016_bib59","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.jaip.2017.04.035","article-title":"Smoking cessation as a possible risk factor for the development of aspirin-exacerbated respiratory disease in smokers","volume":"6","author":"Hayashi","year":"2018","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2022.06.016_bib60","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.jaci.2015.09.028","article-title":"Low E-prostanoid 2 receptor levels and deficient induction of the IL-1beta\/IL-1 type I receptor\/COX-2 pathway: vicious circle in patients with aspirin-exacerbated respiratory disease","volume":"137","author":"Machado-Carvalho","year":"2016","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2022.06.016_bib61","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1111\/j.1365-2222.2008.02989.x","article-title":"Involvement of 15-lipoxygenase and prostaglandin EP receptors in aspirin-triggered 15-hydroxyeicosatetraenoic acid generation in aspirin-sensitive asthmatics","volume":"38","author":"Jedrzejczak-Czechowicz","year":"2008","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.jaip.2022.06.016_bib62","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.3390\/biom10111568","article-title":"Enhanced 15-lipoxygenase 1 production is related to periostin expression and eosinophil recruitment in eosinophilic chronic rhinosinusitis","volume":"10","author":"Imoto","year":"2020","journal-title":"Biomolecules"},{"key":"10.1016\/j.jaip.2022.06.016_bib63","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1038\/nri2273","article-title":"IgE in allergy and asthma today","volume":"8","author":"Gould","year":"2008","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.jaip.2022.06.016_bib64","doi-asserted-by":"crossref","first-page":"121","DOI":"10.4168\/aair.2018.10.2.121","article-title":"Therapeutic effect of omalizumab in severe asthma: a real-world study in Korea","volume":"10","author":"Lee","year":"2018","journal-title":"Allergy Asthma Immunol Res"},{"key":"10.1016\/j.jaip.2022.06.016_bib65","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1038\/nm.2755","article-title":"IgE and mast cells in allergic disease","volume":"18","author":"Galli","year":"2012","journal-title":"Nat Med"},{"key":"10.1016\/j.jaip.2022.06.016_bib66","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.rmed.2011.09.007","article-title":"The role of mast cells in allergic inflammation","volume":"106","author":"Amin","year":"2012","journal-title":"Respir Med"},{"key":"10.1016\/j.jaip.2022.06.016_bib67","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1016\/j.jaci.2004.07.013","article-title":"Staphylococcus aureus colonization and IgE antibody formation to enterotoxins is increased in nasal polyposis","volume":"114","author":"Van Zele","year":"2004","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2022.06.016_bib68","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1067\/mai.2001.112374","article-title":"Total and specific IgE in nasal polyps is related to local eosinophilic inflammation","volume":"107","author":"Bachert","year":"2001","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2022.06.016_bib69","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1016\/j.jaci.2020.02.035","article-title":"IL-5Ralpha marks nasal polyp IgG4- and IgE-expressing cells in aspirin-exacerbated respiratory disease","volume":"145","author":"Buchheit","year":"2020","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2022.06.016_bib70","doi-asserted-by":"crossref","first-page":"3087","DOI":"10.1111\/all.14620","article-title":"Adult-onset eosinophilic airway diseases","volume":"75","author":"Asano","year":"2020","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2022.06.016_bib71","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.anai.2020.09.016","article-title":"Local immunoglobulin production in nasal tissues: a key to pathogenesis in chronic rhinosinusitis with nasal polyps and aspirin-exacerbated respiratory disease","volume":"126","author":"Buchheit","year":"2021","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaip.2022.06.016_bib72","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1164\/rccm.201906-1215OC","article-title":"Omalizumab for aspirin hypersensitivity and leukotriene overproduction in aspirin-exacerbated respiratory disease. A randomized controlled trial","volume":"201","author":"Hayashi","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaip.2022.06.016_bib73","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.jaci.2015.08.023","article-title":"Timing and duration of omalizumab response in patients with chronic idiopathic\/spontaneous urticaria","volume":"137","author":"Kaplan","year":"2016","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2022.06.016_bib74","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1016\/j.jaci.2006.01.046","article-title":"Anti-IgE: lessons learned from effects on airway inflammation and asthma exacerbation","volume":"117","author":"Fahy","year":"2006","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2022.06.016_bib75","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s13601-020-00330-1","article-title":"Effectiveness of omalizumab in patients with severe allergic asthma with and without chronic rhinosinusitis with nasal polyps: a PROXIMA study post hoc analysis","volume":"10","author":"Heffler","year":"2020","journal-title":"Clin Transl Allergy"},{"key":"10.1016\/j.jaip.2022.06.016_bib76","doi-asserted-by":"crossref","first-page":"283","DOI":"10.2500\/aap.2015.36.3849","article-title":"Changes in asthma control, work productivity, and impairment with omalizumab: 5-year EXCELS study results","volume":"36","author":"Zazzali","year":"2015","journal-title":"Allergy Asthma Proc"},{"key":"10.1016\/j.jaip.2022.06.016_bib77","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.rmed.2017.07.013","article-title":"Long-term \u201creal-life\u201d safety of omalizumab in patients with severe uncontrolled asthma: a nine-year study","volume":"130","author":"Di Bona","year":"2017","journal-title":"Respir Med"},{"key":"10.1016\/j.jaip.2022.06.016_bib78","doi-asserted-by":"crossref","DOI":"10.1177\/1753466618810192","article-title":"Omalizumab, the first available antibody for biological treatment of severe asthma: more than a decade of real-life effectiveness","volume":"12","author":"Pelaia","year":"2018","journal-title":"Ther Adv Respir Dis"},{"key":"10.1016\/j.jaip.2022.06.016_bib79","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1111\/j.1365-2222.2004.1916.x","article-title":"Efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma","volume":"34","author":"Holgate","year":"2004","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.jaip.2022.06.016_bib80","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1067\/mai.2001.117880","article-title":"Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma","volume":"108","author":"Busse","year":"2001","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2022.06.016_bib81","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1111\/all.13775","article-title":"Bronchial asthma triggered by house dust mites in patients with local allergic rhinitis","volume":"74","author":"Campo","year":"2019","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2022.06.016_bib82","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.4049\/jimmunol.158.3.1438","article-title":"Down-regulation of Fc(epsilon)RI expression on human basophils during in\u00a0vivo treatment of atopic patients with anti-IgE antibody","volume":"158","author":"MacGlashan","year":"1997","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.jaip.2022.06.016_bib83","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/j.jaci.2006.04.005","article-title":"Anti-IgE as a mast cell-stabilizing therapeutic agent","volume":"117","author":"Chang","year":"2006","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2022.06.016_bib84","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.wjorl.2020.06.002","article-title":"Biologic therapies versus surgical management for aspirin-exacerbated respiratory disease: a review of preliminary data, efficacy, and cost","volume":"6","author":"Workman","year":"2020","journal-title":"World J Otorhinolaryngol Head Neck Surg"},{"key":"10.1016\/j.jaip.2022.06.016_bib85","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1111\/cea.13066","article-title":"Double-blind placebo-controlled trial of the effect of omalizumab on basophils in chronic urticaria patients","volume":"48","author":"Jorg","year":"2018","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.jaip.2022.06.016_bib86","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1111\/cea.12668","article-title":"Comparable actions of omalizumab on mast cells and basophils","volume":"46","author":"Serrano-Candelas","year":"2016","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.jaip.2022.06.016_bib87","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1016\/j.jaci.2015.09.034","article-title":"Omalizumab reduces cysteinyl leukotriene and 9alpha,11beta-prostaglandin F2 overproduction in aspirin-exacerbated respiratory disease","volume":"137","author":"Hayashi","year":"2016","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2022.06.016_bib88","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.anai.2018.05.007","article-title":"Omalizumab can inhibit respiratory reaction during aspirin desensitization","volume":"121","author":"Lang","year":"2018","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaip.2022.06.016_bib89","doi-asserted-by":"crossref","first-page":"AB86","DOI":"10.1016\/j.jaci.2015.12.408","article-title":"Suppression of lipid mediators by the humanized anti-IgE antibody omalizumab in aspirin-exacerbated respiratory disease","volume":"137","author":"Hayashi","year":"2016","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2022.06.016_bib90","doi-asserted-by":"crossref","first-page":"316","DOI":"10.2500\/aap.2019.40.4241","article-title":"Effect of omalizumab on outcomes in patients with aspirin-exacerbated respiratory disease","volume":"40","author":"Jean","year":"2019","journal-title":"Allergy Asthma Proc"},{"key":"10.1016\/j.jaip.2022.06.016_bib91","first-page":"226","article-title":"Omalizumab in patients with NSAIDs-exacerbated respiratory disease","volume":"58","author":"Forster-Ruhrmann","year":"2020","journal-title":"Rhinology"},{"key":"10.1016\/j.jaip.2022.06.016_bib92","doi-asserted-by":"crossref","first-page":"e26","DOI":"10.1002\/ppul.23615","article-title":"Omalizumab in patient with aspirin exacerbated respiratory disease and chronic idiopathic urticaria","volume":"52","author":"Porcaro","year":"2017","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.jaip.2022.06.016_bib93","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.jaip.2015.01.012","article-title":"Omalizumab in the treatment of aspirin-exacerbated respiratory disease","volume":"3","author":"Bergmann","year":"2015","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2022.06.016_bib94","first-page":"448","article-title":"Omalizumab: a potential new therapeutic approach for aspirin-exacerbated respiratory disease","volume":"20","author":"Bobolea","year":"2010","journal-title":"J\u00a0Investig Allergol Clin Immunol"},{"key":"10.1016\/j.jaip.2022.06.016_bib95","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.anai.2015.08.013","article-title":"A\u00a012\u00bd-year journey of a patient with Samter triad syndrome and sporadic omalizumab use","volume":"115","author":"Ardusso","year":"2015","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaip.2022.06.016_bib96","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/j.jaci.2021.07.045","article-title":"Long-term efficacy and safety of omalizumab for nasal polyposis in an open-label extension study","volume":"149","author":"Gevaert","year":"2022","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2022.06.016_bib97","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1177\/19458924211030486","article-title":"Defining the efficacy of omalizumab in nasal polyposis: a POLYP 1 and POLYP 2 subgroup analysis","volume":"36","author":"Damask","year":"2022","journal-title":"Am J Rhinol Allergy"},{"key":"10.1016\/j.jaip.2022.06.016_bib98","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.wjorl.2020.07.001","article-title":"Olfactory outcomes in the management of aspirin exacerbated respiratory disease related chronic rhinosinusitis","volume":"6","author":"Spielman","year":"2020","journal-title":"World J Otorhinolaryngol Head Neck Surg"},{"key":"10.1016\/j.jaip.2022.06.016_bib99","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1186\/s12890-020-01248-x","article-title":"Efficacy of benralizumab for patients with severe eosinophilic asthma: a retrospective, real-life study","volume":"20","author":"Numata","year":"2020","journal-title":"BMC Pulm Med"}],"container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213219822006389?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213219822006389?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T05:35:45Z","timestamp":1761975345000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213219822006389"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":99,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["S2213219822006389"],"URL":"https:\/\/doi.org\/10.1016\/j.jaip.2022.06.016","relation":{},"ISSN":["2213-2198"],"issn-type":[{"value":"2213-2198","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Role of Omalizumab in NSAID-Exacerbated Respiratory Disease: A Narrative Review","name":"articletitle","label":"Article Title"},{"value":"The Journal of Allergy and Clinical Immunology: In Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaip.2022.06.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Inc. on behalf of the American Academy of Allergy, Asthma & Immunology.","name":"copyright","label":"Copyright"}]}}